Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Because of the limited applicability of the different diagnostic scores, another approach based on the major characteristics of PBC and AIH has been proposed and requires the presence of at least 2 of the 3 accepted criteria of both diseases for diagnosing PBC–AIH overlap syndrome (Table 4) [57] whereby histologic evi…”
BackgroundMethodHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
“Given the high specificity of serological markers, liver biopsy is not necessary for the diagnosis of PBC; however, it is still essential when PBC-specific antibodies are absent, or when co-existent AIH or non-alcoholic steatohepatitis (NASH) is suspected.”
InfluentialDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
“The ‘‘Paris criteria’’ are currently the most commonly used tool for diagnosing AIH-PBC variant form as attested by the presence of at least two of the three accepted key criteria of each disease namely, for PBC: 1) alkaline phosphatase (ALP) P2 upper normal limit (ULN) or c-glutamyl-transpeptidase (c-GT) P5 ULN; 2) p…”
BackgroundMethod(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationMack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
“The “Paris criteria” identify patients with overlapping features of AIH and PBC.(177) Two of the following three criteria for PBC should be met: (1) serum alkaline phosphatase level ≥2-fold the upper limit of normal (ULN) range or serum GGT level ≥5-fold ULN, (2) presence of antimitochondrial antibodies (AMA), and (3)…”
BackgroundMethodInfluentialLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“c) Liver biopsy with moderate or severe interface hepatitis.(127)”
BackgroundKrawitt, E. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050408 · Cited by 753
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationBoberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555
“ALT at least 5 ULN and IgG at least 2 ULN, as previously suggested as criteria for AIH [61], may serve as guidelines.”
BackgroundResultInfluentialCorpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
“Ineligibility criteria included a diagnosis of autoimmune hepatitis overlap syndrome as previously defined [17], a positive serology for hepatitis B or C virus, the use of corticosteroids or immunosuppressive drugs for a period of more than 2 months, and a follow-up of less than 1 year.”
BackgroundSelf-citationInvernizzi, P., Podda, M., Battezzati, P. M., Crosignani, A., Zuin, M., Hitchman, E., Maggioni, M., Meroni, P. L., Penner, E., & Wesierska-Gadek, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00040-4 · Cited by 455
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2050 · Cited by 439
“Total bilirubin .257 mmol/L (15 mg/dL) or PT .3 s above the upper reference limit (29 ) in patients with viral hepatitis ALP, alkaline phosphatase (EC 3.1.3.1); PT, prothrombin time; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HBc, hepatitis B virus core antigen; HBsAg, hepatitis B virus su…”
BackgroundInfluentialTang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
“Ineligibility criteria included the presence of an overlap syndrome between PBC and autoimmune hepatitis (”
BackgroundHirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Corpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
“PBC/autoimmune hepatitis (AIH) overlap syndrome was diagnosed when at least two of the following criteria were recorded at any time until or during the study: (1) serum activity of alanine aminotransferase (ALT) at least 5 ULN; (2) serum immunoglobulin G (IgG) level at least 2 ULN or a positive test for anti–smooth mu…”
Self-citationSelmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Alterations of gut microbiome in autoimmune hepatitis
Wei, Y., Li, Y., Yan, L., Sun, C., Miao, Q., Wang, Q., Xiao, X., Lian, M., Li, B., Chen, Y., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317836 · Cited by 305
Heneghan, M. A., Yeoman, A. D., Verma, S., Smith, A. D., & Longhi, M. S. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62163-1 · Cited by 277
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
Czaja, A. J., & Manns, M. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.053 · Cited by 280
Lohse, A. W., zum Büschenfelde, K.-H. M., Franz, B., Kanzler, S., Gerken, G., & Dienes, H.-P. (1999) · Hepatology · doi:10.1002/hep.510290409 · Cited by 278
British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
Gleeson, D., & Heneghan, M. A. (2011) · Gut · doi:10.1136/gut.2010.235259 · Cited by 275
Primary biliary cirrhosis: A 2010 update
Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.027 · Cited by 274
“, presence of two of the three of the following features: (1) ALT activity P5 times upper limits of normal; (2) IgG P2 times upper limits of normal and/or positive anti–smooth muscle antibody; and (3) liver biopsy with moderate or severe periportal or periseptal inflammation [158,159,165].”
BackgroundSelf-citationPrevalence of autoimmune liver disease in Alaska natives
Hurlburt, K. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04376-9 · Cited by 265
“In the 1970s, several studies of patients with PBC and AIH overlap syndrome were reported (13, 16).”
BackgroundMethodDiagnosis and management of autoimmune hepatitis
Muratori, L., Lohse, A. W., & Lenzi, M. (2023) · BMJ · doi:10.1136/bmj-2022-070201 · Cited by 230
“According to the Paris criteria, 70 to identify autoimmune hepatitis overlapping with PBC, two of the following three PBC criteria should be met: serum alkaline phosphatase concentration at least twofold the upper limit of normal or serum γ-glutamyl transferase concentration at least fivefold the…”
BackgroundLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Autoimmune hepatitis: A comprehensive review
Liberal, R., Grant, C. R., Mieli-Vergani, G., & Vergani, D. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.11.002 · Cited by 218
“The AIH criteria include: 1) ALT at least 5 times ULN, 2) IgG at least 2 times ULN or positivity for SMA, and 3) liver biopsy with moderate or severe periportal or periseptal inflammation [116].”
BackgroundDiagnosis and Management of Primary Biliary Cholangitis
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0390-3 · Cited by 211
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Self-citationGatselis, N. K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.60 · Cited by 198
Lohse, A. W., & Mieli-Vergani, G. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.12.012 · Cited by 191
Chazouillères, O., Wendum, D., Serfaty, L., Rosmorduc, O., & Poupon, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.017 · Cited by 194
Self-citationKaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Iacobellis, A., Siciliano, M., Perri, F., Annicchiarico, B. E., Leandro, G., Caruso, N., Accadia, L., Bombardieri, G., & Andriulli, A. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.08.020 · Cited by 192
Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions
Czaja, A. J. (2016) · Gut and Liver · doi:10.5009/gnl15352 · Cited by 183
“Corticosteroids in combination with low dose ursodeoxycholic acid (13 to 15 mg/kg daily) is a common management strategy endorsed by the major liver societies.(105,130-132) The gold standard for the diagnosis is clinical judgment, and the strongest independent predictor of an overlap syndrome is the liver tissue exami…”
BackgroundAutoimmune hepatitis with incidental histologic features of bile duct injury
Czaja, A. J., & Carpenter, H. A. (2001) · Hepatology · doi:10.1053/jhep.2001.27562 · Cited by 189
Review article: autoimmune hepatitis - current management and challenges
Zachou, K., Muratori, P., Koukoulis, G. K., Granito, A., Gatselis, N., Fabbri, A., Dalekos, G. N., & Muratori, L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12470 · Cited by 179
Kumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
“Patients with AMA negative PBC often test positive for high titer ANA and have higher levels of IgG [138] but liver histology indicates no evidence of features of AIH.”
InfluentialHigh prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis
van Buuren, H. R., van Hoogstraten, H. J. F., Terkivatan, T., Schalm, S. W., & Vleggaar, F. P. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80005-7 · Cited by 189
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis
Dalekos, G., Gatselis, N., Drenth, J. P. H., Heneghan, M., Jørgensen, M., Lohse, A. W., Londoño, M., Muratori, L., Papp, M., Samyn, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.017 · Cited by 231
Joshi, S., Cauch-Dudek, K., Wanless, I. R., Lindor, K. D., Jorgensen, R., Batts, K., & Heathcote, J. E. (2002) · Hepatology · doi:10.1053/jhep.2002.30902 · Cited by 174
Degott, C., Zafrani, E. S., Callard, P., Balkau, B., Poupon, R. E., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290444 · Cited by 174
Self-citationDevelopment of autoimmune hepatitis in patients with typical primary biliary cirrhosis
Poupon, R., Chazouilleres, O., Corpechot, C., & Chrétien, Y. (2006) · Hepatology · doi:10.1002/hep.21229 · Cited by 170
Self-citationCorpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Self-citationAutoantibodies in Autoimmune Liver Disease—Clinical and Diagnostic Relevance
Sebode, M., Weiler-Normann, C., Liwinski, T., & Schramm, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00609 · Cited by 158
Chen, W., Wei, Y., Xiong, A., Li, Y., Guan, H., Wang, Q., Miao, Q., Bian, Z., Xiao, X., Lian, M., et al. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08731-2 · Cited by 166
Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes
Silveira, M. G., Talwalkar, J. A., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01136.x · Cited by 165
“The combination of UDCA with immunosuppressive therapy, nevertheless, could potentially provide benefits among patients with PBC and definite overlap (4, 10).”
BackgroundInfluentialRecent updates on the management of autoimmune hepatitis
Komori, A. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0189 · Cited by 187
The diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
“In contrast, fewer than 10% of PBC patients have a more severe hepatocellular injury and other features of AIH including responding to steroids and other immunosuppresants [30].”
Overlap syndromes among autoimmune liver diseases
Rust, C., & Beuers, U. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3368 · Cited by 158
“. However, this conclusion is somewhat controversial, since the treatment was not standardized and no difference was found when the diagnostic criteria proposed by Chazouilleres et al [ 5 ]”
BackgroundMethodResultInfluentialSucher, E., Sucher, R., Gradistanac, T., Brandacher, G., Schneeberger, S., & Berg, T. (2019) · Journal of Immunology Research · doi:10.1155/2019/9437043 · Cited by 170
“The prevalence of AIH-PBC overlap is approximately 10% of adult patients, and special “Paris criteria” [65] exist that depending on the presence of at least two out of three key criteria (which for PBC include (i) increased alkaline phosphatase (ALP) or g-glutamyl-transaminase (g-GT) levels, (ii) presence of antimicro…”
BackgroundPoupon, R. Y., Chazouillères, O., & Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80421-3 · Cited by 169
Self-citationTrauner, & Graziadei (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00596.x · Cited by 151
AL‐CHALABI, T., PORTMANN, B. C., BERNAL, W., MCFARLANE, I. G., & HENEGHAN, M. A. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03722.x · Cited by 149
Czaja, A. J. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328034f234 · Cited by 148
Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
O'Brien, C., Joshi, S., Feld, J. J., Guindi, M., Dienes, H. P., & Heathcote, E. J. (2008) · Hepatology · doi:10.1002/hep.22380 · Cited by 146
Kuiper, E. M. M., Zondervan, P. E., & van Buuren, H. R. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.03.004 · Cited by 152
“s 6 2 (4) 3 (20) 9 (15) IH was 80% and this was comparable with that of the revised coring system (79%).”
ResultRigopoulou, E. I., Davies, E. T., Pares, A., Zachou, K., Liaskos, C., Bogdanos, D.-P., Rodes, J., Dalekos, G. N., & Vergani, D. (2005) · Gut · doi:10.1136/gut.2003.036558 · Cited by 134
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
“teria” (1998) are frequently used in clinical practice [187].”
BackgroundMontano-Loza, A. J., Hansen, B. E., Corpechot, C., Roccarina, D., Thorburn, D., Trivedi, P., Hirschfield, G., McDowell, P., Poupon, R., Dumortier, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.001 · Cited by 129
Self-citationAutoimmune cholangitis within the spectrum of autoimmune liver disease
Czaja, A. J., Carpenter, H. A., Santrach, P. J., & Moore, B. S. (2000) · Hepatology · doi:10.1053/jhep.2000.7878 · Cited by 136
“DR31 (total) 6 (30) 82 (49)a 8 (18) 18 (58)f 19 (19)a,f DR31/DR42 4 (20) 66 (40)c 4 (9) 15 (48)g 14 (14)c,g”
Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
Sarcognato, S., Sacchi, D., Grillo, F., Cazzagon, N., Fabris, L., Cadamuro, M., Cataldo, I., Covelli, C., Mangia, A., & Guido, M. (2021) · Pathologica · doi:10.32074/1591-951x-245 · Cited by 141
Talwalkar, J. A., Keach, J. C., Angulo, P., & Lindor, K. D. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05703.x · Cited by 127
“The existence of overlap between AIH and PBC appears to range from 7% using the original IAHG scoring system (5) to 10% based on specific clinical criteria (6).”
BackgroundReview article: overlap syndromes and autoimmune liver disease
Trivedi, P. J., & Hirschfield, G. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05223.x · Cited by 126
The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome
Muratori, P., Granito, A., Pappas, G., Pendino, G. M., Quarneti, C., Cicola, R., Menichella, R., Ferri, S., Cassani, F., Bianchi, F. B., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.126 · Cited by 125
“During the last decade patients with concomitant biochemical and histological features of AIH and PBC have been described in genetically and environmentally different geographical areas, such as Europe (”
BackgroundAutoimmune hepatitis: Contrasts and comparisons in children and adults – A comprehensive review
Floreani, A., Liberal, R., Vergani, D., & Mieli‐Vergani, G. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.08.004 · Cited by 127
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
Gupta, P., Hart, J., Millis, J. M., Cronin, D., & Brady, L. (2001) · Transplantation · doi:10.1097/00007890-200103150-00016 · Cited by 122
“Patients with variant syndromes respond inconsistently to immunosuppressive therapy (21, 22).”
BackgroundAutoimmune liver disease: overlap and outliers
Washington, M. K. (2007) · Modern Pathology · doi:10.1038/modpathol.3800684 · Cited by 129
“The term ‘overlap syndrome’ is used primarily to describe variant forms of autoimmune liver disease that present with both cholestatic and hepatitic features that do not fit readily into the usual diagnostic categories”
BackgroundCutting edge issues in autoimmune hepatitis
Liberal, R., Krawitt, E. L., Vierling, J. M., Manns, M. P., Mieli‐Vergani, G., & Vergani, D. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.005 · Cited by 129
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
Hasegawa, S., Yoneda, M., Kurita, Y., Nogami, A., Honda, Y., Hosono, K., & Nakajima, A. (2021) · Drugs · doi:10.1007/s40265-021-01545-7 · Cited by 125
Efe, C., Wahlin, S., Ozaslan, E., Berlot, A. H., Purnak, T., Muratori, L., Quarneti, C., Yüksel, O., Thiéfin, G., & Muratori, P. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328350f95b · Cited by 116
Current and potential treatments for primary biliary cholangitis
Shah, R. A., & Kowdley, K. V. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30343-7 · Cited by 115
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis
Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., & Lindor, K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.616 · Cited by 116
Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats
Melgert, B. N., Olinga, P., Van Der Laan, J. M. S., Weert, B., Cho, J., Schuppan, D., Groothuis, G. M. M., Meijer, D. K. F., & Poelstra, K. (2001) · Hepatology · doi:10.1053/jhep.2001.27805 · Cited by 115
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationRising incidence and prevalence of primary biliary cirrhosis: a large population-based study
Boonstra, K., Kunst, A. E., Stadhouders, P. H., Tuynman, H. A., Poen, A. C., van Nieuwkerk, K. M. J., Witteman, E. M., Hamann, D., Witteman, B. J., Beuers, U., et al. (2014) · Liver International · doi:10.1111/liv.12434 · Cited by 112
Novel insights into autoimmune liver diseases provided by genome-wide association studies
Mells, G. F., Kaser, A., & Karlsen, T. H. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.07.004 · Cited by 115
“patients with typical features of one disorder and subtle features of the other [27,30].”
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 124
Woodward, J. M., & Neuberger, J. (2001) · Hepatology · doi:10.1053/jhep.2001.23316 · Cited by 115
The clinical phenotypes of autoimmune hepatitis: A comprehensive review
Wang, Q., Yang, F., Miao, Q., Krawitt, E. L., Gershwin, M. E., & Ma, X. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.10.006 · Cited by 112
“Silveira et al. [94] reported that the 10-year, transplantation-free survival rate of PBCAIH overlap patients was about 55%.”
MethodInfluentialPrimary biliary cirrhosis—presentation and diagnosis
Leuschner, U. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00101-6 · Cited by 106
Autoimmune hepatitis and its variant syndromes
BEN-ARI, Z., & CZAJA, A. J. (2001) · Gut · doi:10.1136/gut.49.4.589 · Cited by 102
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes
Baven-Pronk, A. M. C., Coenraad, M. J., van Buuren, H. R., de Man, R. A., van Erpecum, K. J., Lamers, M. H., Drenth, J. P. H., van den Berg, A. P., Beuers, U. H., den Ouden, J. W., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04727.x · Cited by 102
Lewin, M., Vilgrain, V., Ozenne, V., Lemoine, M., Wendum, D., Paradis, V., Ziol, M., Arrivé, L., Beaugrand, M., Poupon, R., et al. (2009) · Hepatology · doi:10.1002/hep.23024 · Cited by 100
Self-citationCarpenter, H. A., & Czaja, A. J. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00022-3 · Cited by 102
“Transition to a variant or overlap form may also alter management tactics as treatment with ursodeoxycholic acid may be indicated [18,22,90].”
BackgroundZhao, P., & Han, Y. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-1 · Cited by 96
“For the North-American and European population, ANA and SMA constitute the standard repertoire for the diagnosis of autoimmune hepatitis, and AMA is the diagnostic marker of primary biliary cirrhosis [7,16].”
BackgroundMethodDisease-specific autoantibodies in primary biliary cirrhosis
Bogdanos, D. P., & Komorowski, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.12.019 · Cited by 107
Liver transplantation for primary biliary cirrhosis: A long-term pathologic study
Khettry, U., Anand, N., Faul, P. N., Lewis, D. W., Pomfret, E. A., Pomposelli, J., Jenkins, R. L., & Gordon, F. D. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.36392 · Cited by 94
Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis
Poupon, R., Chazouillères, O., Balkau, B., & Poupon, R. E. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80098-1 · Cited by 90
Self-citationWang, G., Tanaka, A., Zhao, H., Jia, J., Ma, X., Harada, K., Wang, F., Wei, L., Wang, Q., Sun, Y. H., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10170-1 · Cited by 102
“0 times ULN and/or positive SMA; (3) Liver biopsy with moderate or severe interface hepatitis [178].”
BackgroundWang, J., Pu, S.-B., Sun, Y. H., Li, Z., Niu, M., Yan, X., Zhao, Y., Wang, L., Qin, X., Ma, Z., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500462f · Cited by 93
Diagnostic considerations for cholestatic liver disease
Pollock, G., & Minuk, G. Y. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13738 · Cited by 92
Diagnosis and Management of the Overlap Syndromes of Autoimmune Hepatitis
Czaja, A. J. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/198070 · Cited by 95
“Serum alkaline phosphatase level and the histological findings of bile duct injury or loss are the principal indicators of this variance, and the strength of the cholestatic component, as reflected in these indexes, directs the management strategy (4,8,19).”
BackgroundInfluentialMuratori, L., Granito, A., Muratori, P., Παππάς, Γ., & Bianchi, F. B. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.009 · Cited by 92
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.